What drugs does Ionis make?
Ionis Pharmaceuticals specializes in pioneering RNA-targeted drug discovery and development using proprietary antisense technology to create innovative medicines for severe diseases. Its commercialized and partnered portfolio features Spinraza for spinal muscular atrophy, Tegsedi and Wainua for hereditary transthyretin-mediated amyloidosis, Qalsody for amyotrophic lateral sclerosis caused by SOD1 mutations, and Olezarsen for severe hypertriglyceridemia. These advanced antisense oligonucleotide therapies modulate protein production at the genetic level to treat rare and metabolic conditions.
Related FAQs
Financial market analysts covering Ionis Pharmaceuticals under the ticker IONS generally assign favorable consensus buy ratings, driven by its leadership in RNA-targeted therapeutics and a growing portfolio of commercialized specialty drugs.
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, exposing investors to high biotechnology clinical development risks.
Ionis Pharmaceuticals, Inc., a pioneer and leader in RNA-targeted drug discovery and antisense technology, is based in Carlsbad, California, United States.
Ionis Pharmaceuticals, Inc. is a leading clinical-stage biotechnology enterprise headquartered in Carlsbad, California, recognized globally as a pioneer in the discovery and development of RNA-targeted therapeutics, particularly antisense medicines.
Ionis Pharmaceuticals, a leading biotechnology pioneer specializing in antisense oligonucleotide therapies, was originally founded and operated under the corporate name Isis Pharmaceuticals.
Ionis Pharmaceuticals maintains its primary global corporate headquarters at 2855 Gazelle Court in Carlsbad, California, United States.
Financial market brokerages covering Ionis Pharmaceuticals under the ticker IONS predominantly assign consensus buy ratings, supported by promising clinical trial readouts, successful drug commercialization progress, and strong institutional backing.
As of August 2026, financial modeling and stock analysis for IonQ, Inc. (IONQ) provide forward-looking price estimates. Market forecasts suggest that the stock price of IonQ could reach approximately $31.99 by the end of 2026.
Ionis Pharmaceuticals maintains an innovative future outlook as a pioneer in RNA-targeted therapeutics, advancing a robust clinical pipeline addressing rare genetic diseases, cardiometabolic conditions, and neurological disorders.
IONOS SE is a massive, publicly traded European cloud hosting and web services enterprise headquartered in Montabaur, Germany, operating as a leading provider of digital presence and cloud solutions for small and medium-sized businesses globally.
Ionis Pharmaceuticals is widely recognized as a pioneering leader and industry innovator in RNA-targeted drug discovery and antisense technology development.
Ionis Pharmaceuticals maintains a strong reputation as an innovative and rewarding scientific employer, offering researchers, clinical specialists, and biotechnology professionals structured career advancement, competitive compensation packages, and ...
Financial market analysts evaluating IonQ as a long-term investment weigh its pioneering role in trapped-ion quantum computing, rapid revenue scaling, and large multi-year booking backlogs against significant operating cash burn and high volatility.
Ionis Pharmaceuticals operates as a fully public corporate entity, having completed its initial public offering to list its common shares on the Nasdaq Global Select Market under the ticker symbol IONS.
Ionis Pharmaceuticals possesses a promising future anchored by its pioneering leadership in RNA-targeted therapeutics and antisense technology.
Joby Aviation is frequently compared to Tesla because it is attempting to pioneer a new category of transportation: electric vertical take-off and landing (eVTOL) aircraft.
Equity research brokerages covering Ionis Pharmaceuticals frequently recommend it as an attractive long-term investment within the biotechnology sector, driven by its proprietary RNA-targeting technology platform and growing commercial product revenu...
Ionis Pharmaceuticals, Inc. is a leading American biotechnology enterprise that pioneered and specializes in RNA-targeted drug discovery and development. The corporate name derives conceptually from nucleic acids and RNA science.
Financial market analysts evaluating Ionis Pharmaceuticals generally view the biotechnology enterprise as a compelling purchase opportunity, supported by its pioneering leadership in RNA-targeted therapeutics and a robust commercial pipeline.